You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EPOCH

Showing 1 - 25 of 436
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

T Cell Lymphoma Trial in New Haven (Mogamulizumab, DA-EPOCH Protocol)

Not yet recruiting
  • T Cell Lymphoma
  • New Haven, Connecticut
    Yale Smilow Cancer Hospital
Aug 14, 2023

Richter Syndrome Trial in United States (Venetoclax, DA-EPOCH-R, R-CHOP)

Recruiting
  • Richter Syndrome
  • Boston, Massachusetts
  • +2 more
Jan 6, 2023

Hodgkin Lymphoma, DLBCL Trial run by the NCI (campath, Rituximab, EPOCH)

Completed
Has Results
  • Hodgkin Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Campath
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 11, 2022

DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Active, not recruiting
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • +4 more
  • EPOCH
  • Rituximab
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Ovarian Carcinosarcoma, Uterine Carcinosarcoma Trial (Eribulin Mesylate, Pembrolizumab)

Not yet recruiting
  • Ovarian Carcinosarcoma
  • Uterine Carcinosarcoma
  • (no location specified)
Jan 31, 2023

Lymphoma, AIDS-related, Lymphoma, Large B-Cell, Diffuse Trial run by the NCI (Rituximab, Filgrastim, EPOCH)

Active, not recruiting
Has Results
  • Lymphoma, AIDS-related
  • Lymphoma, Large B-Cell, Diffuse
  • Rituximab
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Jul 21, 2022

Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Recruiting
  • Diffuse Large Cell Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,

Suspended
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

AIDS Related Lymphoma, AIDS-Associated Lymphoma Trial run by the NCI (Filgrastim, Rituximab, EPOCH)

Completed
  • AIDS Related Lymphoma
  • AIDS-Associated Lymphoma
  • Filgrastim
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Jan 18, 2022

Mantle Cell Lymphoma, Lymphoma, Mantle Cell Trial run by the NCI (EPOCH-R, GM-CSF, Idiotype vaccine)

Completed
Has Results
  • Mantle Cell Lymphoma
  • Lymphoma, Mantle Cell
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Jan 4, 2023

Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid, Non-Hodgkins Lymphoma Trial run by the NCI (Interferon, Rituxan and

Recruiting
  • Lymphomatoid Granulomatosis
  • +3 more
  • Interferon
  • Rituxan and EPOCH
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell Trial run by the NCI (Alemtuzumab (Campath), EPOCH)

Completed
Has Results
  • Lymphoma, T-Cell
  • Lymphoma, Extranodal NK-T-Cell
  • Alemtuzumab (Campath)
  • EPOCH
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Feb 3, 2022

Lymphoma, Mantle Cell, Mantle Cell Lymphoma Trial run by the NCI (Rituximab (R), EPOCH, Bortezomib (B))

Active, not recruiting
Has Results
  • Lymphoma, Mantle Cell
  • Mantle Cell Lymphoma
  • Rituximab (R)
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 21, 2021

DLBCL, High Grade B-Cell Lymphoma Trial in United States (Venetoclax, Rituximab, Etoposide)

Completed
  • Diffuse Large B-Cell Lymphoma
  • High Grade B-Cell Lymphoma
  • Boston, Massachusetts
  • +5 more
Aug 23, 2022

B-cell Lymphoma, Burkitt Lymphoma Trial in Milwaukee (Etoposide, Doxorubicin, Cyclophosphamide)

Not yet recruiting
  • B-cell Lymphoma
  • Burkitt Lymphoma
  • Milwaukee, Wisconsin
    Froedtert Hospital & the Medical College of Wisconsin
Jun 11, 2022

T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma Trial run

Completed
Has Results
  • T-Cell Peripheral Lymphoma
  • +3 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Oct 28, 2021

Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma Trial in Belgium, Netherlands (DA-EPOCH-R followed by

Active, not recruiting
  • Non Hodgkin Lymphoma
  • +4 more
  • DA-EPOCH-R followed by Nivolumab
  • Antwerpen, Belgium
  • +23 more
Mar 23, 2022

Post-operative Pain, Post-operative Delirium, Post-cardiac Surgery Trial in Toronto (Intermittent Superficial Parasternal

Recruiting
  • Post-operative Pain
  • +5 more
  • Intermittent Superficial Parasternal Intercostal Plane Block - Experimental
  • Intermittent Superficial Parasternal Intercostal Plane Block - Sham
  • Toronto, Ontario, Canada
    St. Michael's Hospital
Sep 13, 2023

Peripheral T Cell Lymphoma Trial in Duarte, Aurora, Philadelphia (Nivolumab and EPOCH)

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Nivolumab and EPOCH
  • Duarte, California
  • +2 more
Jan 6, 2023

Newborn Heart Rate as a Catalyst for Improved Survival

Completed
  • Stillbirth
  • +3 more
  • Epoch 2: HBB with NeoBeat
  • Epoch 3: HR-guided HBB
  • Kinshasa, Congo, The Democratic Republic of the
  • +2 more
Mar 29, 2022

Lymphoma Trial in Washington, Baltimore (rituximab, sargramostim, EPOCH regimen)

Withdrawn
  • Lymphoma
  • rituximab
  • +7 more
  • Washington, District of Columbia
  • +1 more
Oct 19, 2021

Richter Transformation Trial in China (R-EPOCH in Combination With Ibrutinib)

Not yet recruiting
  • Richter Transformation
  • R-EPOCH in Combination With Ibrutinib
  • Beijing, Beijing, China
  • +10 more
Jul 29, 2021

Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma Trial in Bethesda, Minneapolis (biological, drug,

Recruiting
  • Myelodysplastic Syndrome
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
  • +1 more
Aug 20, 2022

High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements,

Recruiting
  • High Grade B-Cell Lymphoma, Not Otherwise Specified
  • +4 more
  • Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
  • R-CHOP; R-DA-EPOCH; R-HD MTX
  • Jinan, Shandong, China
    Department of Hematology, Shandong Provincial Hospital
Dec 7, 2021

Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma Trial in United States (EPOCH-R,

Active, not recruiting
Has Results
  • Burkitt Lymphoma
  • +2 more
  • La Jolla, California
  • +29 more
Nov 2, 2021